Clinical Trial 43911

Oakland, CA 94607


Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term outcomes remains challenging.

This study will assess the safety, efficacy and tolerability of brexpiprazole as adjunctive therapy to protocol-specific open-label antidepressant therapy.

Qualified Participants Must:

• Be age 18-65
• Subjects with both a diagnosis of recurrent major depressive disorder, and in a current major depressive episode of 8 weeks or more in duration
• Subjects must have reported a history for the current major depressive episode of an inadequate response to 1 or 2 adequate antidepressant treatments

Qualified Participants May Receive:

Compensation for time and travel, study-related treatment and investigational drug or placebo.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.